Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on...

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Class IIa HDACs bind MEF2 transcription factors in leiomyosarcoma, promoting cancer cell proliferation.
• Disrupting the HDAC-MEF2 complex with small molecules is a potential anti-cancer strategy.
• NKL54, a PAOA derivative, interacts with MEF2 but its primary mechanism (HDAC inhibition vs. complex disruption) was unclear.

Purpose of the Study:

• To elucidate the mechanism of action of NKL54 and related compounds in leiomyosarcoma.
• To determine whether NKL54 disrupts the MEF2-HDAC complex or acts as a histone deacetylase inhibitor (HDACI).
• To investigate the downstream effects of NKL54 on gene expression and apoptosis.

Main Methods:

• Comparative transcriptomic analysis of NKL54-treated cells.
• Analysis of MEF2 binding to class IIa HDACs.
• Assessment of H3K27 acetylation patterns.
• Evaluation of BH3-only gene expression and apoptosis induction.
• Measurement of MEF2D binding to gene promoters.

Main Results:

• NKL54 and derivatives function as HDACIs, similar to SAHA/vorinostat, and do not release MEF2 from class IIa HDACs.
• HDAC inhibition by NKL54 leads to upregulation of low-expressed genes and repression of abundant genes, altering chromatin acetylation.
• NKL54 treatment upregulates pro-apoptotic BH3-only genes, inducing apoptosis.
• NKL54 increases MEF2 expression, decreases class IIa HDAC levels, and enhances MEF2D binding to target gene promoters.

Conclusions:

• NKL54 is a potent HDACI that promotes apoptosis in leiomyosarcoma.
• While not disrupting the HDAC-MEF2 complex, NKL54 enhances MEF2-dependent transcription through multiple mechanisms, including increased chromatin binding.
• NKL54 represents a promising therapeutic strategy for leiomyosarcoma by modulating epigenetic regulation and inducing cell death.